Terms: = Bone cancer AND SH2B3, LNK, 10019, ENSG00000111252, Q9UQQ2
14 results:
1. Somatic homozygous loss of sh2b3, and a non-Robertsonian translocation t(15;21)(q25.3;q22.1) with NTRK3 rearrangement, in an adolescent with progenitor B-cell acute lymphoblastic leukemia with the iAMP21.
Capela de Matos RR; Othman M; Ferreira GM; Monteso K; de Souza MT; Rouxinol M; Melo JB; Carreira IM; Abdelhay E; Liehr T; Ribeiro RC; Silva M
Cancer Genet; 2022 Apr; 262-263():16-22. PubMed ID: 34974289
[TBL] [Abstract] [Full Text] [Related]
2. Hereditary Predisposition to Hematopoietic Neoplasms: When Bloodline Matters for Blood cancers.
Mangaonkar AA; Patnaik MM
Mayo Clin Proc; 2020 Jul; 95(7):1482-1498. PubMed ID: 32571604
[TBL] [Abstract] [Full Text] [Related]
3. The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants.
Rio-Machin A; Vulliamy T; Hug N; Walne A; Tawana K; Cardoso S; Ellison A; Pontikos N; Wang J; Tummala H; Al Seraihi AFH; Alnajar J; Bewicke-Copley F; Armes H; Barnett M; Bloor A; Bödör C; Bowen D; Fenaux P; Green A; Hallahan A; Hjorth-Hansen H; Hossain U; Killick S; Lawson S; Layton M; Male AM; Marsh J; Mehta P; Mous R; Nomdedéu JF; Owen C; Pavlu J; Payne EM; Protheroe RE; Preudhomme C; Pujol-Moix N; Renneville A; Russell N; Saggar A; Sciuccati G; Taussig D; Toze CL; Uyttebroeck A; Vandenberghe P; Schlegelberger B; Ripperger T; Steinemann D; Wu J; Mason J; Page P; Akiki S; Reay K; Cavenagh JD; Plagnol V; Caceres JF; Fitzgibbon J; Dokal I
Nat Commun; 2020 Feb; 11(1):1044. PubMed ID: 32098966
[TBL] [Abstract] [Full Text] [Related]
4. Allogeneic stem cell transplantation in patients with myelofibrosis harboring the MPL mutation.
Mannina D; Gagelmann N; Badbaran A; Ditschkowski M; Bogdanov R; Robin M; Cassinat B; Heuser M; Shahswar R; Thol F; Beelen D; Kröger N
Eur J Haematol; 2019 Dec; 103(6):552-557. PubMed ID: 31446640
[TBL] [Abstract] [Full Text] [Related]
5. Telomere length and its correlation with gene mutations in chronic lymphocytic leukemia in a Korean population.
Song DY; Kim JA; Jeong D; Yun J; Kim SM; Lim K; Park SN; Im K; Choi S; Yoon SS; Lee DS
PLoS One; 2019; 14(7):e0220177. PubMed ID: 31335885
[TBL] [Abstract] [Full Text] [Related]
6. lnk/sh2b3 deficiency restores hematopoietic stem cell function and genome integrity in Fancd2 deficient Fanconi anemia.
Balcerek J; Jiang J; Li Y; Jiang Q; Holdreith N; Singh B; Chandra V; Lv K; Ren JG; Rozenova K; Li W; Greenberg RA; Tong W
Nat Commun; 2018 Sep; 9(1):3915. PubMed ID: 30254368
[TBL] [Abstract] [Full Text] [Related]
7. Prognostication in Philadelphia Chromosome Negative Myeloproliferative Neoplasms: a Review of the Recent Literature.
Zhou A; Afzal A; Oh ST
Curr Hematol Malig Rep; 2017 Oct; 12(5):397-405. PubMed ID: 28948488
[TBL] [Abstract] [Full Text] [Related]
8. lnk/sh2b3 Loss of Function Promotes Atherosclerosis and Thrombosis.
Wang W; Tang Y; Wang Y; Tascau L; Balcerek J; Tong W; Levine RL; Welch C; Tall AR; Wang N
Circ Res; 2016 Sep; 119(6):e91-e103. PubMed ID: 27430239
[TBL] [Abstract] [Full Text] [Related]
9. Co-existence of IL7R high and sh2b3 low expression distinguishes a novel high-risk acute lymphoblastic leukemia with Ikaros dysfunction.
Ge Z; Gu Y; Xiao L; Han Q; Li J; Chen B; Yu J; Kawasawa YI; Payne KJ; Dovat S; Song C
Oncotarget; 2016 Jul; 7(29):46014-46027. PubMed ID: 27322554
[TBL] [Abstract] [Full Text] [Related]
10. Rare and low-frequency coding variants in CXCR2 and other genes are associated with hematological traits.
Auer PL; Teumer A; Schick U; O'Shaughnessy A; Lo KS; Chami N; Carlson C; de Denus S; Dubé MP; Haessler J; Jackson RD; Kooperberg C; Perreault LP; Nauck M; Peters U; Rioux JD; Schmidt F; Turcot V; Völker U; Völzke H; Greinacher A; Hsu L; Tardif JC; Diaz GA; Reiner AP; Lettre G
Nat Genet; 2014 Jun; 46(6):629-34. PubMed ID: 24777453
[TBL] [Abstract] [Full Text] [Related]
11. Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.
Tibes R; Bogenberger JM; Benson KL; Mesa RA
Mol Diagn Ther; 2012 Oct; 16(5):269-83. PubMed ID: 23023734
[TBL] [Abstract] [Full Text] [Related]
12. JAK2 inhibitors in the treatment of myeloproliferative neoplasms.
Tibes R; Bogenberger JM; Geyer HL; Mesa RA
Expert Opin Investig Drugs; 2012 Dec; 21(12):1755-74. PubMed ID: 22991927
[TBL] [Abstract] [Full Text] [Related]
13. Myeloproliferative neoplasms: from JAK2 mutations discovery to JAK2 inhibitor therapies.
Passamonti F; Maffioli M; Caramazza D; Cazzola M
Oncotarget; 2011 Jun; 2(6):485-90. PubMed ID: 21646683
[TBL] [Abstract] [Full Text] [Related]
14. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.
Tefferi A; Vainchenker W
J Clin Oncol; 2011 Feb; 29(5):573-82. PubMed ID: 21220604
[TBL] [Abstract] [Full Text] [Related]
